Northern, WI - (Expedated) - Acura Pharma (NASDAQ:ACUR) has had a few volatile days on the back of the deal with Kerr Drug store chain will carry Acura's drug Nexafed, a decongestant that is designed to be difficult to make into methamphetamine.
Acura said Nexafed should be on shelves in Kerr's approximately 75 locations in North Carolina. Acura began selling Nexafed in December and said it expected early interest from independent drug stores rather than chains.
Nexafed is a form of the decongestant pseudoephedrine. It contains inactive ingredients that turn into a thick gel if anyone tries to extract the pseudoephedrine. That means the chemical won't crystallize and can't be made into crystal meth. The Palatine, Ill., company said Nexafed will deliver the same cold and allergy relief as other versions of pseudoephedrine and it will cost about as much as similar cold and allergy remedies.
Legislators have taken steps in recent years to combat meth, including a law that took effect this year requiring retailers to enter information about the sale of medications that contains pseudoephedrine onto a national online tracking system.
Acura reported its fourth-quarter results Monday, and said that by the end of February it has entered distribution agreements with most national and regional drug wholesalers. The company said it took a loss of $3 million, or 6 cents per share, after taking a loss of $1.6 million, or 3 cents per share, in the final quarter of 2011. The company had no revenue in either quarter.
Acura lost $9.7 million, or 20 cents per share, in 2012 and reported no revenue. A year earlier Acura reported net income of $10.4 million, or 22 cents per share. The company reported $20.5 million in revenue in 2011, mostly from payments related to Pfizer Inc.'s pain drug Oxecta.
Oxecta is an immediate-release drug that contains oxycodone, the active ingredient in OxyContin. It was approved in the U.S. in 2011 and uses Acura's Aversion technology to discourage abuse by crushing and inhaling them or dissolving them for injection.
About Expedated Financial:
Expedated is a prominent marketing firm, specializing in small cap, micro cap, and penny stocks. When investing in penny stocks it’s imperative to follow your investment closely, and have up to the minute information on the given company.
Expedated can be your source of information. Sign up today at www.EXPEDATED.com
Our philosophy is that small cap investments provide above average gains. We conduct extensive due diligence on companies everyday, and only alert our subscribers to the ones that fit the criteria of suiting potential.
Join us today as an email recipient of our alerts and see for yourself the potential and leverage we offer to succeed in today’s trading markets!
Disclaimer:
EXPEDATED.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Expedated.com website, for complete risks and disclosures.
Contact:
www.EXPEDATED.com
[email protected]